with floating immunobeads . Bone Marrow Transplant 1990; 
6:301-307. 
83. Gobbi M, Cavo M, Tazzari PL, et al. Autologous bone marrow 
transplantation with immunotoxin-purged marrow for advanced 
multiple "myeloma. Eur : J~HaematolSuppl r 1989? '51rl76-181' 
••84 Caligaris-Cappio F, Bergui L, Tesio-L,- et al. Identification 
of malignant plasma cell precursors in the bone marrow of 
multiple myeloma. J Clin Invest 1985; 76:1243-1251. 
85. * Epstein J, Xiao" H, He X-Y. Markers of "muTtiple 
hematopoietic-cell lineages in multiple myeloma. N E J M 1990; 
322:664-668. 
86. Graham-Pole J, Gee A, Emerson S, et al. Myeloablative 
chemoradiotherapy and autologus bone marrow infusions for 
treatment of neuroblastoma: factors influencing engraftment. 
Blood 1991; 78:1607-1614. • 
APPENDIX A 
Dartmouth Transplant Criteria: 
Score 
0 PMNs never < 500/ul, platelets never < 10,000/ul 
1 PMNs > 500/ul, platelets > 10,000 within 4 wks post-BMT 
2 PMNs > 500/ul, platelets > 10,000 4-8 wks post-BMT 
3 PMNs > 500/ul, platelets > 10,000 beyond 8 wks post-BMT 
4 Death due to bacterial or fungal infection, or 
hemorrhage associated with PMNs < 500/ul, platelets < 
10,000/ul more than 8 wks post-BMT. 
Recombinant DNA Research, Volume 16 
[69] 
